Aileron Therapeutics is a clinical stage oncology company based in Boston. The company's focus is on developing ALRN-6924, an innovative treatment for a range of cancers. ALRN-6924 is currently in Phase 1 and 2a clinical trials for solid tumors, lymphoma, and various other cancer types.